Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease

A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of PRX002 Administered By Intravenous Infusion in Patients With Parkinson's Disease

This multiple ascending dose study is to determine safety, tolerability, pharmacokinetics and immunogenicity of PRX002 in approximately 60 patients with Parkinson's disease.

Inclusion Criteria:

• Idiopathic Parkinson's disease, Hoehn and Yahr 1-3
• Body weight range of ≥ 45kg/99 lbs to ≤ 110 kg/242 lbs
• Female subjects must be surgically sterile or post-menopausal or if of child-bearing potential must use contraception
• Male subjects and their partners of childbearing potential must use contraception

Exclusion Criteria:

• Significant cardiac history
• Abnormal MRI
• Significant laboratory abnormalities